



## InflaRx to Present at Upcoming Scientific and Investor Conferences

**Jena, Germany, September 9, 2022** – InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced its participation at several conferences.

**H.C. Wainwright 24<sup>th</sup> Annual Global Investment Conference, New York, NY USA:** Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, will provide a general corporate overview and update on **Wednesday, September 14<sup>th</sup> at 9:30 am EDT (3:30 pm CEST)**. A link to the live stream of the presentation and a replay following the live event will be provided on the InflaRx website in the Investors – Events & Presentations section.

**10<sup>th</sup> World Sepsis Day, Berlin, Germany:** Prof. Riedemann will participate in a podium discussion organized by the Global Sepsis Alliance and the German Sepsis Foundation on **September 16<sup>th</sup>**. In advance of the event, a press conference was held on September 9<sup>th</sup> at the German Federal Press Conference (“Bundespressekonferenz”) at which Prof. Riedemann discussed “Innovative Therapeutics in Viral Sepsis.”

**6<sup>th</sup> Complement Drug Development Summit, Boston, MA USA:** Prof. Dr. Renfeng Guo, Chief Scientific Officer and Co-founder of InflaRx, will give a presentation on **Wednesday, September 28<sup>th</sup>** entitled, “Treatment of Critically Ill COVID-19 Patients with Vilobelimab, a First-in-Class Anti-C5a Antibody.”

**35<sup>th</sup> Annual Congress, European Society for Intensive Care Medicine (ESICM), Paris, France:** Prof. Dr. Alexander Vlaar, principal investigator of the PANAMO Phase III trial, will present a [poster](#) on October 24 entitled, “Vilobelimab Treatment in Mechanically Ventilated Patients with COVID-19: A Randomized Controlled Phase III Trial.”



### **About InflaRx N.V.**

InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary technology to discover and develop first-in-class or best-in-class, potent and specific inhibitors of C5a and C5aR. Complement C5a and its receptor C5aR are powerful inflammatory mediators involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit [www.inflarx.com](http://www.inflarx.com).

### **Contacts:**

#### **InflaRx N.V.**

Email: [IR@inflarx.de](mailto:IR@inflarx.de)

#### **MC Services AG**

Katja Arnold, Laurie Doyle, Andreas Jungfer

Email: [inflarx@mc-services.eu](mailto:inflarx@mc-services.eu)

Europe: +49 89-210 2280

US: +1-339-832-0752

### **FORWARD-LOOKING STATEMENTS**

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential” or “continue” and similar expressions. Forward-looking statements appear in a number of places throughout this release and may include statements regarding InflaRx’s intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, the Company’s ongoing and planned pre-clinical development and clinical trials, including the development of vilobelimab in several indications; the Company’s interactions with regulators regarding the results of clinical trials and potential regulatory approval pathways; the Company’s submission of an application to the FDA in the third quarter of 2022 for emergency use authorization for vilobelimab to treat critically ill COVID-19 patients; the impact of the COVID-19 pandemic on the Company; the timing and its ability to commence and conduct clinical trials; potential results from current or potential future collaborations; its ability to make regulatory filings, obtain positive guidance from regulators and obtain and maintain regulatory approvals for its product candidates; its intellectual property position; its ability to develop commercial functions; expectations regarding clinical trial data; decisions regarding the strategic direction of the Company; its results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies; the industry in which the Company operates; the trends that



may affect the industry or the Company; and the risks, uncertainties and other factors described under the heading "Risk Factors" in InflaRx's periodic filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and InflaRx assumes no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.